FD is a rare neurodegenerative disorder caused by a mutation of the IKBKAP gene, which induces low expression levels of the Elongator subunit IKAP/hELP1 protein. A rational strategy for FD treatment could be to identify drugs increasing IKAP/hELP1 expression levels by blocking protein degradation pathways such as the 26S proteasome. Proteasome inhibitors are promising molecules emerging in cancer treatment and could thus constitute an enticing pharmaceutical strategy for FD treatment. Therefore, we tested three proteasome inhibitors on FD human olfactory ecto-mesenchymal stem cells (hOE-MSCs): two approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), bortezomib and carfilzomib, as well as epoxomicin. Although all 3 inhibitors demonstrated activity in correcting IKBKAP mRNA aberrant splicing, carfilzomib was superior in enhancing IKAP/hELP1 quantity. Moreover, we observed a synergistic effect of suboptimal doses of carfilzomib on kinetin in improving IKBKAP isoforms ratio and IKAP/hELP1 expression levels allowing to counterbalance carfilzomib toxicity. Finally, we identified several dysregulated miRNAs after carfilzomib treatment that target proteasome-associated mRNAs and determined that IKAP/hELP1 deficiency in FD pathology is correlated to an overactivity of the 26S proteasome. Altogether, these results reinforce the rationale for using chemical compounds inhibiting the 26S proteasome as an innovative option for FD and a promising therapeutic pathway for many other neurodegenerative diseases.
Introduction
Familial dysautonomia (FD, also known as Riley Day syndrome or Hereditary Sensory Autonomic Neuropathy type III, MIM 223900) is a neurodevelopmental, autosomal recessive disorder that exclusively affects the Ashkenazi Jewish population with an incidence of 1:3700 live births. This neurodegenerative orphan disease is characterized by a progressive degeneration of fibers from the autonomic and sensory nervous system, which results in clinical manifestations such as pain and temperature sensation loss, gastrointestinal and cardiovascular deficits, dysautonomic crises and complications. No curative treatment is currently available and, despite development of palliative care, about 50% of patients die before reaching 40 years old (Norcliffe-Kaufmann et al., 2016) .
FD is caused by mutations affecting the IKBKAP gene (Anderson et al., 2001; Slaugenhaupt et al., 2001) . The most common mutation, which occurs in 99.5% of FD patients, is a T to C transition in position 6 of the donor splice site (5'ss) of intron 20 of the IKBKAP gene (c.2204+6TNC). This mutation leads to an alternative splicing profile of this gene resulting in expression of both IKBKAP WT (exon 20 inclusion) and MU (exon 20 skipping) transcripts, which leads to a decreased synthesis of IKAP/hELP1 protein specifically in nervous system tissues (Cuajungco et al., 2003) .
IKAP/hELP1 is a 150-kDa scaffold protein of a well-conserved sixsubunit complex, named Elongator (Glatt and Muller, 2013; Hawkes et al., 2002; Xu et al., 2015) . At present, the function of IKAP/hElongator is not clearly understood, but it was identified as playing a role in processes such as transcription elongation, α-tubulin acetylation, intracellular trafficking, exocytosis and tRNA post-transcriptional modifications (Creppe and Buschbeck, 2011; Karlsborn et al., 2014; Svejstrup, 2007) . Moreover, IKAP/hELP1 has an essential function in nervous system development, notably in neuronal cell survival, migration and differentiation (Abashidze et al., 2014; Chaverra et al., 2017; Cheishvili et al., 2007; Creppe et al., 2009; Hunnicutt et al., 2012; Jackson et al., 2014; Lefler et al., 2015) .
The design of therapeutic strategies is highly dependent on the quality of disease modeling. Cellular models constitute interesting tools but, in the case of an orphan genetic disease like FD, samples are scarce. Therefore, in vitro models derived from easily accessible cells were Neurobiology of Disease 103 (2017) 113-122 
